Abilify Potential Safety Issues Flagged By FDA In Quarterly AERS Review
Executive Summary
FDA is evaluating a number of possible safety signals related to Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole), according to a 1report posted to the agency's Web site Feb. 4
You may also be interested in...
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.